Cargando…
Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers
BACKGROUND: Urocortin 2 and urocortin 3 are endogenous peptides with an emerging role in cardiovascular pathophysiology. We assessed their pharmacodynamic profile and examined the role of the endothelium in mediating their vasomotor effects in vivo in man. METHODS AND RESULTS: Eighteen healthy male...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603262/ https://www.ncbi.nlm.nih.gov/pubmed/23525432 http://dx.doi.org/10.1161/JAHA.112.004267 |
_version_ | 1782263660232572928 |
---|---|
author | Venkatasubramanian, Sowmya Griffiths, Megan E. McLean, Steven G. Miller, Mark R. Luo, Rosa Lang, Ninian N. Newby, David E. |
author_facet | Venkatasubramanian, Sowmya Griffiths, Megan E. McLean, Steven G. Miller, Mark R. Luo, Rosa Lang, Ninian N. Newby, David E. |
author_sort | Venkatasubramanian, Sowmya |
collection | PubMed |
description | BACKGROUND: Urocortin 2 and urocortin 3 are endogenous peptides with an emerging role in cardiovascular pathophysiology. We assessed their pharmacodynamic profile and examined the role of the endothelium in mediating their vasomotor effects in vivo in man. METHODS AND RESULTS: Eighteen healthy male volunteers (23±4 years) were recruited into a series of double‐blind, randomized crossover studies using bilateral forearm venous occlusion plethysmography during intra‐arterial urocortin 2 (3.6 to 120 pmol/min), urocortin 3 (1.2 to 36 nmol/min), and substance P (2 to 8 pmol/min) in the presence or absence of inhibitors of cyclooxygenase (aspirin), cytochrome P450 metabolites of arachidonic acid (fluconazole), and nitric oxide synthase (L‐NMMA). Urocortins 2 and 3 evoked arterial vasodilatation (P<0.0001) without tachyphylaxis but with a slow onset and offset of action. Inhibition of nitric oxide synthase with L‐NMMA reduced vasodilatation to substance P and urocortin 2 (P≤0.001 for both) but had little effect on urocortin 3 (P>0.05). Neither aspirin nor fluconazole affected vasodilatation induced by any of the infusions (P>0.05 for all). In the presence of all 3 inhibitors, urocortin 2– and urocortin 3–induced vasodilatation was attenuated (P<0.001 for all) to a greater extent than with L‐NMMA alone (P≤0.005). CONCLUSIONS: Urocortins 2 and 3 cause potent and prolonged arterial vasodilatation without tachyphylaxis. These vasomotor responses are at least partly mediated by endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid. The role of urocortins 2 and 3 remains to be explored in the setting of human heart failure, but they have the potential to have major therapeutic benefits. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov//. Unique identifier: NCT01096706 and NCT01296607. |
format | Online Article Text |
id | pubmed-3603262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36032622013-03-27 Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers Venkatasubramanian, Sowmya Griffiths, Megan E. McLean, Steven G. Miller, Mark R. Luo, Rosa Lang, Ninian N. Newby, David E. J Am Heart Assoc Original Research BACKGROUND: Urocortin 2 and urocortin 3 are endogenous peptides with an emerging role in cardiovascular pathophysiology. We assessed their pharmacodynamic profile and examined the role of the endothelium in mediating their vasomotor effects in vivo in man. METHODS AND RESULTS: Eighteen healthy male volunteers (23±4 years) were recruited into a series of double‐blind, randomized crossover studies using bilateral forearm venous occlusion plethysmography during intra‐arterial urocortin 2 (3.6 to 120 pmol/min), urocortin 3 (1.2 to 36 nmol/min), and substance P (2 to 8 pmol/min) in the presence or absence of inhibitors of cyclooxygenase (aspirin), cytochrome P450 metabolites of arachidonic acid (fluconazole), and nitric oxide synthase (L‐NMMA). Urocortins 2 and 3 evoked arterial vasodilatation (P<0.0001) without tachyphylaxis but with a slow onset and offset of action. Inhibition of nitric oxide synthase with L‐NMMA reduced vasodilatation to substance P and urocortin 2 (P≤0.001 for both) but had little effect on urocortin 3 (P>0.05). Neither aspirin nor fluconazole affected vasodilatation induced by any of the infusions (P>0.05 for all). In the presence of all 3 inhibitors, urocortin 2– and urocortin 3–induced vasodilatation was attenuated (P<0.001 for all) to a greater extent than with L‐NMMA alone (P≤0.005). CONCLUSIONS: Urocortins 2 and 3 cause potent and prolonged arterial vasodilatation without tachyphylaxis. These vasomotor responses are at least partly mediated by endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid. The role of urocortins 2 and 3 remains to be explored in the setting of human heart failure, but they have the potential to have major therapeutic benefits. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov//. Unique identifier: NCT01096706 and NCT01296607. Blackwell Publishing Ltd 2013-02-22 /pmc/articles/PMC3603262/ /pubmed/23525432 http://dx.doi.org/10.1161/JAHA.112.004267 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Venkatasubramanian, Sowmya Griffiths, Megan E. McLean, Steven G. Miller, Mark R. Luo, Rosa Lang, Ninian N. Newby, David E. Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title | Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title_full | Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title_fullStr | Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title_full_unstemmed | Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title_short | Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers |
title_sort | vascular effects of urocortins 2 and 3 in healthy volunteers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603262/ https://www.ncbi.nlm.nih.gov/pubmed/23525432 http://dx.doi.org/10.1161/JAHA.112.004267 |
work_keys_str_mv | AT venkatasubramaniansowmya vasculareffectsofurocortins2and3inhealthyvolunteers AT griffithsmegane vasculareffectsofurocortins2and3inhealthyvolunteers AT mcleansteveng vasculareffectsofurocortins2and3inhealthyvolunteers AT millermarkr vasculareffectsofurocortins2and3inhealthyvolunteers AT luorosa vasculareffectsofurocortins2and3inhealthyvolunteers AT langniniann vasculareffectsofurocortins2and3inhealthyvolunteers AT newbydavide vasculareffectsofurocortins2and3inhealthyvolunteers |